HEALTHCARE RESOURCE UTILIZATION (HCRU) AND COSTS IN PATIENTS WITH METASTATIC UROTHELIAL CANCER (MUC) WHO RECEIVED FIRST-LINE (1L) TREATMENT: RESULTS FROM IMPACT UC II

被引：0
|
作者：
Bilen, M. A. [1 ]
Diessner, B. [2 ]
White, J. [2 ]
Kirker, M. [3 ]
Liu, F. [4 ]
Nguyen, A. [2 ]
Gharibian, N. [3 ]
Devgan, G. [3 ]
Katzenstein, H. [4 ]
Bhanegaonkar, A. [4 ]
机构：
[1] Winship Canc Inst Emory Univ, Atlanta, GA USA
[2] Optum, Eden Prairie, MN USA
[3] Pfizer, New York, NY USA
[4] EMD Serono, Rockland, MA USA
来源：
VALUE IN HEALTH | 2023年 / 26卷 / 06期
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
EE390
引用
收藏
页码：S131 / S131
页数：1
相关论文
共 50 条
  • [31] CLINICAL AND HEALTH-RELATED QUALITY OF LIFE (HRQOL) OUTCOMES FROM INTERVENTIONAL STUDIES IN FIRST-LINE (1L) ADVANCED OR METASTATIC UROTHELIAL CANCER (MUC): A SYSTEMATIC LITERATURE REVIEW (SLR)
    Braun, N.
    Auti, P.
    Arca, E.
    Teitsson, S.
    Broughton, E.
    May, J. R.
    Kurt, M.
    Alleman, C.
    VALUE IN HEALTH, 2022, 25 (01) : S19 - S19
  • [32] First-line avelumab for patients with PD-L1-positive metastatic or locally advanced urothelial cancer who are unfit for cisplatin
    Iacovelli, R.
    Ciccarese, C.
    Brunelli, M.
    Battelli, N.
    Buttigliero, C.
    Caserta, C.
    Buti, S.
    Santini, D.
    Carella, C.
    Galli, L.
    Verri, E.
    Ermacora, P.
    Merler, S.
    Masini, C.
    De Vivo, R.
    Milesi, L.
    Spina, F.
    Rizzo, M.
    Sperduti, I.
    Fornarini, G.
    Tortora, G.
    ANNALS OF ONCOLOGY, 2022, 33 (11) : 1179 - 1185
  • [33] Split-dose cisplatin plus gemcitabine use and associated clinical outcomes in the first-line (1L) treatment of locally advanced or metastatic urothelial cancer (la/mUC): Results of a retrospective observational study in Germany (CONVINCE)
    Schlack, K.
    Kubin, T.
    Ruhnke, M.
    Schulte, C.
    Machtens, S.
    Eisen, A.
    Osowski, U.
    Guenther, S.
    Kearney, M.
    Lipp, R.
    Schmitz, S.
    ANNALS OF ONCOLOGY, 2023, 34 : S1216 - S1216
  • [34] Long-term outcomes in patients with advanced urothelial carcinoma (UC) who received avelumab first-line (1 L) maintenance with or without second-line (2 L) treatment: Exploratory analyses from JAVELIN Bladder 100
    Bellmunt, Joaquim
    Powles, Thomas
    Duran, Miguel A. Climent
    Sridhar, Srikala S.
    Gurney, Howard
    Pook, David W.
    Costa, Nuno
    Di Pietro, Alessandra
    Huang, Bo
    Gupta, Shilpa
    Grivas, Petros
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2022, 18 : 137 - 138
  • [35] IMvigor210: updated analyses of first-line (1L) atezolizumab (atezo) in cisplatin (cis)-ineligible locally advanced/metastatic urothelial carcinoma (mUC)
    Bellmunt, J.
    Balar, A.
    Galsky, M. D.
    Loriot, Y.
    Theodore, C.
    Grande Pulido, E.
    Castellano, D.
    Retz, M.
    Niegisch, G.
    Bracarda, S.
    Necchi, A.
    Vaishampayan, U.
    Sridhar, S.
    Eigl, B. J.
    Hussain, S.
    van der Heijden, M.
    Danner, B.
    Mariathasan, S.
    Legrand, F.
    Rosenberg, J. E.
    ANNALS OF ONCOLOGY, 2016, 27
  • [36] AVELUMAB FIRST-LINE (1L) MAINTENANCE FOR ADVANCED UROTHELIAL CARCINOMA (UC): LONG-TERM OUTCOMES FROM JAVELIN BLADDER 100 IN SUBGROUPS DEFINED BY RESPONSE TO 1L CHEMOTHERAPY
    Valderrama, Begona
    Powles, Thomas
    Sridhar, Srikala
    Caserta, Claudia
    Loriot, Yohann
    Gupta, Shilpa
    Bellmunt, Joaquim
    Sternberg, Cora
    Wang, Jing
    Costa, Nuno
    Laliberte, Robert
    di Pietro, Alessandra
    Park, Se Hoon
    Grivas, Petros
    JOURNAL OF UROLOGY, 2023, 209 : E244 - E244
  • [37] REAL-WORLD PRODUCTIVITY, HEALTHCARE RESOURCE UTILIZATION (HCRU) AND QUALITY OF LIFE (QOL) IN PATIENTS RECEIVING FIRST-LINE TREATMENT FOR ADVANCED GASTRIC CANCER (GC) IN CANADA AND EUROPE
    Rider, A.
    Calvo, E.
    Bertwistle, D.
    Hall, J.
    Higson, O.
    Moon, R.
    VALUE IN HEALTH, 2019, 22 : S112 - S112
  • [38] Healthcare resource utilization (HCRU), costs, and mortality in relation to select immune-related adverse events (irAEs) and line of therapy (LOT) in patients (pts) with advanced or metastatic urothelial cancer (UC) treated with immune checkpoint inhibitor (ICI) monotherapy.
    George, Saby
    Zheng, Ying
    Bell, Elizabeth
    Engel-Nitz, Nicole
    White, John C.
    Lal, Lincy S.
    Yang Mo
    Devgan, Geeta
    Smith, Jodi
    Kim, Ruth
    Liu, Frank Xiaoqing
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (06)
  • [39] AVAILABILITY OF PUBLISHED HEALTH-RELATED QUALITY OF LIFE (HRQOL) DATA FOR PATIENTS RECEIVING FIRST-LINE (1L) TREATMENT FOR ADVANCED OR METASTATIC UROTHELIAL CARCINOMA (MUC): A SYSTEMATIC LITERATURE REVIEW (SLR)
    Auti, P.
    Arca, E.
    Braun, N.
    Teitsson, S.
    Broughton, E.
    May, J. R.
    Kurt, M.
    Alleman, C.
    VALUE IN HEALTH, 2022, 25 (01) : S226 - S226
  • [40] Real-world outcomes in patients (pts) with metastatic urothelial carcinoma (mUC) who received first- (1L) or second-line (2L) PD-1 and PD-L1 inhibitors in the United States (US)
    Boyd, M.
    Annavarapu, S.
    Doshi, G. K.
    Imai, K.
    Sbar, E. I.
    Godwin, J. L.
    Li, H.
    Sonpavde, G.
    ANNALS OF ONCOLOGY, 2020, 31 : S599 - S599
12345